Literature DB >> 14569398

Reduced Fhit protein expression in human malignant mesothelioma.

Lea Pylkkänen1, Henrik Wolff, Tuula Stjernvall, Aija Knuuttila, Sisko Anttila, Kirsti Husgafvel-Pursiainen.   

Abstract

Human malignant mesothelioma (MM) is an aggressive neoplasm related to occupational exposure to asbestos and characterised by a long latency time. Multiple chromosomal deletions and DNA losses have been revealed in MM by studies performed with karyotypic, comparative genomic hybridisation and loss of heterozygosity (LOH) analyses. Among frequently deleted chromosomal sites, LOH at chromosome 3p has been detected in MM, suggesting the presence of one or several tumour suppressor genes that have an important role in development of the disease. The FHIT (fragile histidine triad) tumour suppressor gene, located at 3p14.2, has been proposed to be a target to major human lung carcinogens, such as tobacco smoke and asbestos. Although many studies have indicated decreased Fhit protein expression in a variety of malignancies, there is no report of FHIT gene aberrations or Fhit protein abnormalities in MM. We examined expression of the Fhit protein and LOH at the FHIT gene in malignant mesothelioma. Altogether, 13 paraffin embedded MM tumours were analysed for Fhit protein expression, and 21 fresh tumours and 10 cell cultures for LOH at the FHIT gene with two intragenic microsatellite markers. All tumours showed less intense immunostaining than normal bronchial epithelium or mesothelium. Fhit expression was absent or reduced in 54% (7 of 13) of the tumours, with the weakest staining observed in poorly differentiated areas. Allele loss was seen in 3 of 10 (30%) of the MM cell lines, but only in 1 of the 21 fresh tumours studied, suggesting concealment of LOH by normal cells present in MM tumours. In conclusion, our present data indicate a frequent decrease of Fhit protein expression, thus supporting the significance of FHIT inactivation in development of MM.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14569398     DOI: 10.1007/s00428-003-0902-3

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  35 in total

1.  Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos.

Authors:  H H Nelson; J K Wiencke; L Gunn; J C Wain; D C Christiani; K T Kelsey
Journal:  Cancer Res       Date:  1998-05-01       Impact factor: 12.701

Review 2.  Somatic genetic alterations in human malignant mesothelioma (review).

Authors:  W C Lee; J R Testa
Journal:  Int J Oncol       Date:  1999-01       Impact factor: 5.650

3.  The FHIT gene is expressed in pancreatic ductular cells and is altered in pancreatic cancers.

Authors:  C Sorio; A Baron; S Orlandini; G Zamboni; P Pederzoli; K Huebner; A Scarpa
Journal:  Cancer Res       Date:  1999-03-15       Impact factor: 12.701

4.  FHIT alterations in cancerous and non-cancerous cervical epithelium.

Authors:  K Yoshino; T Enomoto; T Nakamura; H Sun; K Ozaki; R Nakashima; H Wada; J Saitoh; Y Watanabe; K Noda; Y Murata
Journal:  Int J Cancer       Date:  2000-01-01       Impact factor: 7.396

Review 5.  The pathogenesis of asbestos-associated diseases.

Authors:  J E Craighead; B T Mossman
Journal:  N Engl J Med       Date:  1982-06-17       Impact factor: 91.245

6.  Loss of FHIT expression in transitional cell carcinoma of the urinary bladder.

Authors:  R Baffa; L G Gomella; A Vecchione; P Bassi; K Mimori; J Sedor; C M Calviello; M Gardiman; C Minimo; S E Strup; P A McCue; A J Kovatich; F Pagano; K Huebner; C M Croce
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

7.  Muir-Torre-like syndrome in Fhit-deficient mice.

Authors:  L Y Fong; V Fidanza; N Zanesi; L F Lock; L D Siracusa; R Mancini; Z Siprashvili; M Ottey; S E Martin; T Druck; P A McCue; C M Croce; K Huebner
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

8.  Loss of FHIT function in lung cancer and preinvasive bronchial lesions.

Authors:  G Sozzi; U Pastorino; L Moiraghi; E Tagliabue; F Pezzella; C Ghirelli; S Tornielli; L Sard; K Huebner; M A Pierotti; C M Croce; S Pilotti
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

9.  Asbestos-related malignant mesothelioma: growth, cytology, tumorigenicity and consistent chromosome findings in cell lines from five patients.

Authors:  K Pelin-Enlund; K Husgafvel-Pursiainen; L Tammilehto; M Klockars; K Jantunen; B I Gerwin; C C Harris; T Tuomi; E Vanhala; K Mattson
Journal:  Carcinogenesis       Date:  1990-04       Impact factor: 4.944

Review 10.  Additional techniques in serous effusions.

Authors:  A G J M Hanselaar
Journal:  Anal Cell Pathol       Date:  2002       Impact factor: 2.916

View more
  3 in total

1.  Hypomethylation reduced the aggressive potential of human malignant mesothelioma cells.

Authors:  N-Y Kim; M-C Kim; Y Kim
Journal:  Cancer Gene Ther       Date:  2016-11-18       Impact factor: 5.987

2.  Expression of cancer-associated molecules in malignant mesothelioma.

Authors:  Ben Davidson
Journal:  Biomark Insights       Date:  2007-05-30

3.  Microenvironment-Dependent Phenotypic Changes in a SCID Mouse Model for Malignant Mesothelioma.

Authors:  Eva Darai-Ramqvist; Gustav Nilsonne; Carmen Flores-Staino; Anders Hjerpe; Katalin Dobra
Journal:  Front Oncol       Date:  2013-08-09       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.